Ascend Biopharmaceuticals Ltd.

January 17, 2025 Stamford has announced positive results for its ASN-002-003 multi-lesional clinical trial (NCT 04416516. Protocol No ASN-002-003) evaluating SP-002, an Adenovirus-5 replication deficient vector encoding human Interferon- in combination with vismodegib (a Hedgehog Pathway Inhibitor) in subjects presenting with multiple BCCs. “We are very pleased with these positive results from the Phase 2 study demonstrating the safety and efficacy of our gene therapy for patients with multiple nodular and superficial BCCs. We are particularly excited that the histopathologic criteria, which would allow responsive patients to be identified at screening and used for patient selection. This histopathologic criterion was first noted in the ASN-002-001 clinical study and has now been successfully reproduced in ASN-002-003. We believe this enables us to develop a useful treatment option for patients with nodular BCC and addresses the important need for a non-surgical option for those with BCCs in the H-zone or for those who are not ideal candidates for surgery.” Dr Clement Leong (PhD), CEO of Stamford Pharmaceuticals Press Release: Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients